Syros to Present at 2019 Wedbush PacGrow Healthcare Conference
August 06 2019 - 4:01PM
Business Wire
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development
of medicines that control the expression of genes, today announced
that its Chief Financial Officer, Joseph J. Ferra, will present a
corporate overview at the 2019 Wedbush PacGrow Healthcare
Conference. Details are as follows:
2019 Wedbush PacGrow Healthcare Conference: Date:
Tuesday, August 13 Time: 3:40 p.m. ET Location: The Parker New
York, 119 West 56th Street, New York, NY
A live webcast of the presentation will be available on the
Investors & Media section of the Syros website at
www.syros.com. An archived replay will be available for
approximately 30 days following the fireside chat.
About Syros Pharmaceuticals Syros is pioneering the
understanding of the non-coding regulatory region of the genome to
advance a new wave of medicines that control the expression of
genes. Syros has built a proprietary platform that is designed to
systematically and efficiently analyze this unexploited region of
DNA to identify and drug novel targets linked to genomically
defined patient populations. Because gene expression is fundamental
to the function of all cells, Syros’ gene control platform has
broad potential to create medicines that achieve profound and
durable benefit across a range of diseases. Syros is currently
focused on cancer and monogenic diseases and is advancing a growing
pipeline of gene control medicines. Syros’ lead drug candidates are
SY-1425, a selective RARα agonist in a Phase 2 clinical trial for
genomically defined subsets of patients with acute myeloid
leukemia, and SY-1365, a selective CDK7 inhibitor in a Phase 1
clinical trial focused on patients with ovarian and breast cancers.
Syros is also developing a deep preclinical and discovery pipeline,
including SY-5609, an oral CDK7 inhibitor, as well as programs in
oncology and sickle cell disease. Led by a team with deep
experience in drug discovery, development and commercialization,
Syros is located in Cambridge, Mass.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190806005668/en/
Media Contact: Naomi Aoki Syros Pharmaceuticals
617-283-4298 naoki@syros.com Investor Contact: Hannah
Deresiewicz Stern Investor Relations, Inc. 212-362-1200
hannah.deresiewicz@sternir.com
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Syros Pharmaceuticals (NASDAQ:SYRS)
Historical Stock Chart
From Apr 2023 to Apr 2024